Tyra Biosciences, INC Form 4 insider transactions

RA Capital Management, a significant shareholder and director of Tyra Biosciences, Inc., has substantially increased its beneficial ownership through recent open market purchases of common stock.

Tyra Biosciences, Inc. Director Robert J. More was granted 22,200 stock options with an exercise price of $9.25 as part of the company's Non-Employee Director Compensation Program.

Tyra Biosciences, Inc. Director Susan Moran was granted 22,200 stock options with an exercise price of $9.25 as part of the company's Non-Employee Director Compensation Program.

Tyra Biosciences, Inc. Director Stephen Michael Rothenberg was granted 22,200 stock options as part of the company's Non-Employee Director Compensation Program.

Tyra Biosciences, Inc. Director Gilla Kaplan was granted 22,200 stock options with an exercise price of $9.25 as part of the company's Non-Employee Director Compensation Program.

RA Capital Management and its affiliates, including director Jake Simson, reported the grant of 22,200 stock options in Tyra Biosciences, Inc. as part of the company's non-employee director compensation program.

Tyra Biosciences, Inc. Director Rehan Verjee was granted 22,200 stock options with an exercise price of $9.25, vesting monthly over one year.

Tyra Biosciences Director Jake Simson was granted 22,200 stock options with an exercise price of $9.25, which will vest monthly over a year, though he disclaims beneficial ownership as they are held for RA Capital Management funds.

Tyra Biosciences' CEO, Todd Harris, increased his holdings in the company by acquiring 1,241 shares of common stock through the 2021 Employee Stock Purchase Plan.

Alan Fuhrman, CFO of Tyra Biosciences, acquired 1,238 shares of common stock under the company's 2021 Employee Stock Purchase Plan at a price of $9.775 per share.

Director Nina S. Kjellson reports the sale of Tyra Biosciences (TYRA) common stock on February 5, 2025.

Director Adele M. Gulfo acquired 37,200 stock options in Tyra Biosciences on January 29, 2025, according to a Form 4 filing.

Director Nina S. Kjellson reports selling 4,825 shares of Tyra Biosciences (TYRA) at an average price of $16.2624 on January 23, 2025.

Director Nina Kjellson of Tyra Biosciences sold shares indirectly through related investment entities in multiple transactions between January 16th and January 21st, 2025.

Director Nina S. Kjellson of Tyra Biosciences sold a portion of her holdings in common stock through indirect ownership.

RA Capital Management, along with related entities and individuals, has acquired over 1.2 million shares of Tyra Biosciences at a price of $16.25 per share.

Director Nina S. Kjellson reported the sale of Tyra Biosciences (TYRA) stock held indirectly through investment partnerships.

Director Nina S. Kjellson reported the sale of Tyra Biosciences (TYRA) common stock through indirect holdings via Canaan XI L.P. and 2020+ Co-Investment L.P. Series 7.

Nina Kjellson, a director at Tyra Biosciences, reported the sale of common stock over several transactions between October 30 and November 1, 2024.

Alan Fuhrman, CFO of Tyra Biosciences, recently purchased 9,500 shares of the company's common stock at an average price of $15.9952 per share.

Boxer Capital Management, LLC exchanged 2,000,000 shares of Tyra Biosciences common stock for a pre-funded warrant to purchase the same number of shares.

Tyra Biosciences' CEO, Todd Harris, sold shares of common stock on October 18 and 21, 2024, under a pre-arranged 10b5-1 trading plan.

RA Capital Healthcare Fund exchanged 1,000,000 shares of Tyra Biosciences' common stock for pre-funded warrants exercisable for the same number of shares at a nominal price.

Tyra Biosciences' CEO, Todd Harris, executed multiple sales of common stock between October 15 and October 17, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Tyra Biosciences CEO Todd Harris sold 500 shares of common stock at $24 per share on September 30, 2024, according to a Form 4 filing.

Tyra Biosciences' CEO, Todd Harris, executed multiple sales of common stock between September 23rd and September 25th, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Tyra Biosciences CEO Todd Harris sold shares of the company's common stock between September 18 and September 20, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Todd Harris, President and CEO of Tyra Biosciences, acquired 1,350 shares of common stock through the company's Employee Stock Purchase Plan on September 13, 2024.

Alan Fuhrman, CFO of Tyra Biosciences, acquired 954 shares of common stock through the company's Employee Stock Purchase Plan on September 13, 2024.

Douglas J. Warner, Chief Medical Officer of Tyra Biosciences, acquired 260,000 stock options on September 9, 2024.